Prime Medicine Q3 net loss $52.5M; BMS collaboration provides $110M upfront

Prime Medicine, Inc.

2024-Q3 EPS reported -$1.34 revenue$800,000

Net loss of $52.5M in Q3 2024 vs. $50.7M in Q3 2023; R&D expenses $40.3M, G&A $14.1M.
Pro-forma cash $244.6M, sufficient to fund operations into 1H 2026.
Entered strategic collaboration with Bristol Myers Squibb for ex vivo T-cell therapies; $110M upfront (including $55M equity investment), potential milestones >$3.5B.
Wilson's Disease program initiated IND-enabling activities; IND/CTA filing expected 1H 2026.
Phase 1/2 trial of PM359 for p47 phox CGD ongoing; initial clinical data expected in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.